Ignite Creation Date:
2024-05-06 @ 8:06 PM
Last Modification Date:
2024-10-26 @ 3:20 PM
Study NCT ID:
NCT06254807
Status:
RECRUITING
Last Update Posted:
2024-04-11
First Post:
2024-02-02
Brief Title:
CAR-monocytes for the Treatment of HER2 Overexpressing Solid Tumors
Sponsor:
Carisma Therapeutics Inc
Organization:
Carisma Therapeutics Inc
Study Overview
Official Title:
An Open-Label Single-Arm Study of Autologous Anti-HER2 Chimeric Antigen Receptor Monocytes CT-0525 in Participants With HER2 Over Expressing Solid Tumors
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a first-in-human open-label study to evaluate the safety and tolerability and manufacturing feasibility of anti-HER2 CAR-monocytes CT-0525 in participants with locally advanced unresectable or metastatic solid tumors overexpressing HER2 whose disease has progressed on standard approved therapies
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None